Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis

[ad_1]

  • 1.
    • Häuser W
    • Finn DP
    • Kalso E
    • et al.

    European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management.

    Eur J Pain. 2018; 22: 1547-1564

  • 2.

    Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients.

    Int J Drug Policy. 2017; 42: 30-35

  • 3.
    • Witkin JM
    • Tzavara ET
    • Davis RJ
    • Li X
    • Nomikos GG

    A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders.

    Trends Pharmacol Sci. 2005; 26: 609-617

  • 4.

    The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD).

    Front Behav Neurosci. 2013; 7: 100

  • 5.
    • Bergamaschi MM
    • Queiroz RHC
    • Chagas MHN
    • et al.

    Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

    Neuropsychopharmacology. 2011; 36: 1219-1226

  • 6.
    • Müller-Vahl KR
    • Kolbe H
    • Schneider U
    • Emrich HM

    Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome.

    Acta Psychiatr Scand. 1998; 98: 502-506

  • 7.
    • Bonn-Miller MO
    • Boden MT
    • Bucossi MM
    • Babson KA

    Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users.

    Am J Drug Alcohol Abuse. 2014; 40: 23-30

  • 8.
    • Sarvet AL
    • Wall MM
    • Keyes KM
    • Olfson M
    • Cerdá M
    • Hasin DS

    Self-medication of mood and anxiety disorders with marijuana: higher in states with medical marijuana laws.

    Drug Alcohol Depend. 2018; 186: 10-15

  • 9.
    • Whiting PF
    • Wolff RF
    • Deshpande S
    • et al.

    Cannabinoids for medical use: a systematic review and meta-analysis.

    JAMA. 2015; 313: 2456-2473

  • 10.
    • Wilkinson ST
    • Radhakrishnan R
    • D’Souza DC

    A systematic review of the evidence for medical marijuana in psychiatric indications.

    J Clin Psychiatry. 2016; 77: 1050-1064

  • 11.
    • National Academies of Sciences Engineering and Medicine

    The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research.

    The National Academies Press,
    Washington, DC2017

  • 12.
    • Kessler RC
    • Amminger GP
    • Aguilar-Gaxiola S
    • Alonso J
    • Lee S
    • Ustün TB

    Age of onset of mental disorders: a review of recent literature.

    Curr Opin Psychiatry. 2007; 20: 359-364

  • 13.
    • Stockings E
    • Campbell G
    • Hall WD
    • et al.

    Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies.

    Pain. 2018; 159: 1932-1954

  • 14.
    • Stockings E
    • Zagic D
    • Campbell G
    • et al.

    Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence.

    J Neurol Neurosurg Psychiatry. 2018; 89: 741-753

  • 15.
    • Higgins JP
    • Altman DG
    • Gøtzsche PC
    • et al.
    • the Cochrane Bias Methods Group
    • the Cochrane Statistical Methods Group

    The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.

    BMJ. 2011; 343d5928

  • 16.
    • Schunemann H
    • Higgins JPT
    • Vist GE
    • et al.

    In: Chapter 14. Completing “Summary of findings” tables and grading the certainty of the evidence. Draft version.

    in: Higgins J Cochrane Handbook for Systematic Reviews of Interventions. Cochrane,
    London2019

  • 17.

    Statistical power analysis for the behavioral sciences.

    Routledge Academic,
    New York, NY1988

  • 18.
    • Deeks J
    • Higgins J
    • Altman D

    In: Chapter 9. Analysing data and undertaking metaanalyses.

    in: Higgins J Churchill R Chandler J Cumpston M Cochrane Handbook for Systematic Reviews of Interventions. Cochrane,
    London2017

  • 19.
    • Abrams DI
    • Jay CA
    • Shade SB
    • et al.

    Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial.

    Neurology. 2007; 68: 515-521

  • 20.
    • Aragona M
    • Onesti E
    • Tomassini V
    • et al.

    Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.

    Clin Neuropharmacol. 2009; 32: 41-47

  • 21.
    • Attal N
    • Brasseur L
    • Guirimand D
    • Clermond-Gnamien S
    • Atlami S
    • Bouhassira D

    Are oral cannabinoids safe and effective in refractory neuropathic pain?.

    Eur J Pain. 2004; 8: 173-177

  • 22.
    • Bahorik AL
    • Leibowitz A
    • Sterling SA
    • Travis A
    • Weisner C
    • Satre DD

    Patterns of marijuana use among psychiatry patients with depression and its impact on recovery.

    J Affect Disord. 2017; 213: 168-171

  • 23.
    • Ball S
    • Vickery J
    • Hobart J
    • et al.

    The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.

    Health Technol Assess. 2015; 19: 1-187

  • 24.
    • Bellnier T
    • Brown G
    • Ortega T
    • Insull R

    A preliminary evaluation of the effcacy, safety, and costs associated with the treatment of chronic pain with medical marijuana in the elderly.

    Consult Pharm. 2017; 32: 597

  • 25.

    An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy.

    Pain Pract. 2011; 11: 353-368

  • 26.

    Treating depression with cannabinoids.

    Cannabinoids. 2008; 3: 8-10

  • 27.
    • Clermont-Gnamien S
    • Atlani S
    • Attal N
    • Le Mercier F
    • Guirimand F
    • Brasseur L

    [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain].

    Presse Med. 2002; 31: 1840-1845

  • 28.
    • Ellis RJ
    • Toperoff W
    • Vaida F
    • et al.

    Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial.

    Neuropsychopharmacology. 2009; 34: 672-680

  • 29.
    • Frank B
    • Serpell MG
    • Hughes J
    • Matthews JN
    • Kapur D

    Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study.

    BMJ. 2008; 336: 199-201

  • 30.
    • Gerardi MC
    • Batticciotto A
    • Talotta R
    • Ditto MC
    • Atzeni F
    • Sarzi-Puttini P

    Efficacy of cannabis flos in patients with fibromyalgia: a monocentric observational study.

    Arthritis Rheumatol. 2016; 68: 72-74

  • 31.
    • Gruber AJ
    • Pope Jr, HG
    • Brown ME

    Do patients use marijuana as an antidepressant?.

    Depression. 1996; 4: 77-80

  • 32.
    • Hagenbach U
    • Luz S
    • Ghafoor N
    • et al.

    The treatment of spasticity with Δ9-tetrahydrocannabinol in persons with spinal cord injury.

    Spinal Cord. 2007; 45: 551-562

  • 33.
    • Haroutiunian S
    • Rosen G
    • Shouval R
    • Davidson E

    Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain.

    J Pain Palliat Care Pharmacother. 2008; 22: 213-217

  • 34.
    • Johnson MJ
    • Pierce JD
    • Mavandadi S
    • et al.

    Mental health symptom severity in cannabis using and non-using Veterans with probable PTSD.

    J Affect Disord. 2016; 190: 439-442

  • 35.
    • Lahat A
    • Lang A
    • Ben-Horin S

    Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study.

    Digestion. 2012; 85: 1-8

  • 36.
    • Malik Z
    • Bayman L
    • Valestin J
    • Rizvi-Toner A
    • Hashmi S
    • Schey R

    Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial.

    Dis Esophagus. 2017; 30: 1-8

  • 37.
    • Martínez-Rodríguez JE
    • Munteis E
    • Carreño M
    • et al.

    Cannabis use in Spanish patients with multiple sclerosis: fulfilment of patients’ expectations?.

    J Neurol Sci. 2008; 273: 103-107

  • 38.
    • Maurer M
    • Henn V
    • Dittrich A
    • Hofmann A

    Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial.

    Eur Arch Psychiatry Clin Neurosci. 1990; 240: 1-4

  • 39.
    • López-Sendón Moreno JL
    • García Caldentey J
    • Trigo Cubillo P
    • et al.

    A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease.

    J Neurol. 2016; 263: 1390-1400

  • 40.
    • Müller-Vahl KR
    • Koblenz A
    • Jöbges M
    • Kolbe H
    • Emrich HM
    • Schneider U

    Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance.

    Pharmacopsychiatry. 2001; 34: 19-24

  • 41.
    • Narang S
    • Gibson D
    • Wasan AD
    • et al.

    Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy.

    J Pain. 2008; 9: 254-264

  • 42.
    • Neff GW
    • O’Brien CB
    • Reddy KR
    • et al.

    Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.

    Am J Gastroenterol. 2002; 97: 2117-2119

  • 43.
    • Notcutt W
    • Price M
    • Miller R
    • et al.

    Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies.

    Anaesthesia. 2004; 59: 440-452

  • 44.
    • Novotna A
    • Mares J
    • Ratcliffe S
    • et al.
    • the Sativex Spasticity Study Group

    A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

    Eur J Neurol. 2011; 18: 1122-1131

  • 45.
    • Pini LA
    • Guerzoni S
    • Cainazzo MM
    • et al.

    Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial.

    J Headache Pain. 2012; 13: 677-684

  • 46.
    • Portenoy RK
    • Ganae-Motan ED
    • Allende S
    • et al.

    Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.

    J Pain. 2012; 13: 438-449

  • 47.
    • Rog DJ
    • Nurmikko TJ
    • Friede T
    • Young CA

    Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

    Neurology. 2005; 65: 812-819

  • 48.
    • Rudich Z
    • Stinson J
    • Jeavons M
    • Brown SC

    Treatment of chronic intractable neuropathic pain with dronabinol: case report of two adolescents.

    Pain Res Manag. 2003; 8: 221-224

  • 49.
    • Shah A
    • Craner J
    • Cunningham JL

    Medical cannabis use among patients with chronic pain in an interdisciplinary pain rehabilitation program: characterization and treatment outcomes.

    J Subst Abuse Treat. 2017; 77: 95-100

  • 50.
    • Toth C
    • Mawani S
    • Brady S
    • et al.

    An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain.

    Pain. 2012; 153: 2073-2082

  • 51.
    • van Amerongen G
    • Kanhai K
    • Baakman AC
    • et al.

    Effects on spasticity and neuropathic pain of an oral formulation of Δ9-tetrahydrocannabinol in patients with progressive multiple sclerosis.

    Clin Ther. 2017; 40: 1467-1482

  • 52.
    • Wade DT
    • Makela P
    • Robson P
    • House H
    • Bateman C

    Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.

    Mult Scler. 2004; 10: 434-441

  • 53.
    • Ware MA
    • Wang T
    • Shapiro S
    • et al.
    • the COMPASS study team

    Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).

    J Pain. 2015; 16: 1233-1242

  • 54.
    • Ware MA
    • Wang T
    • Shapiro S
    • et al.

    Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.

    CMAJ. 2010; 182: E694-E701

  • 55.
    • Weber J
    • Schley M
    • Casutt M
    • et al.

    Tetrahydrocannabinol (Delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: results of a multicenter survey.

    Anesthesiol Res Pract. 2009; 2009827290

  • 56.
    • Weber M
    • Goldman B
    • Truniger S

    Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial.

    J Neurol Neurosurg Psychiatry. 2010; 81: 1135-1140

  • 57.
    • Wilsey B
    • Marcotte T
    • Tsodikov A
    • et al.

    A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

    J Pain. 2008; 9: 506-521

  • 58.
    • Zajicek J
    • Fox P
    • Sanders H
    • et al.
    • the UK MS Research Group

    Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

    Lancet. 2003; 362: 1517-1526

  • 59.
    • Zajicek JP
    • Sanders HP
    • Wright DE
    • et al.

    Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

    J Neurol Neurosurg Psychiatry. 2005; 76: 1664-1669

  • 60.
    • Crippa JAS
    • Derenusson GN
    • Ferrari TB
    • et al.

    Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.

    J Psychopharmacol. 2011; 25: 121-130

  • 61.
    • de Vries M
    • van Rijckevorsel DCM
    • Vissers KCP
    • Wilder-Smith OHG
    • van Goor H
    • the Pain and Nociception Neuroscience Research Group

    Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study.

    Clin Gastroenterol Hepatol. 2017; 15: 1079-1086.e4

  • 62.
    • Deutsch SI
    • Rosse RB
    • Connor JM
    • Burket JA
    • Murphy ME
    • Fox FJ

    Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol.

    CNS Spectr. 2008; 13: 393-403

  • 63.

    The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety.

    J Clin Pharmacol. 1981; 21: 377S-382S

  • 64.
    • Glass RM
    • Uhlenhuth EH
    • Hartel FW
    • Schuster CR
    • Fischman MW

    Single-dose study of nabilone in anxious volunteers.

    J Clin Pharmacol. 1981; 21: 383S-396S

  • 65.
    • Leehey M
    • Liu Y
    • Epstein C
    • et al.

    Open label study of cannabidiol in Parkinson’s disease.

    Mov Disord. 2017; 32: 913

  • 66.
    • Müller-Vahl KR
    • Schneider U
    • Prevedel H
    • et al.

    Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.

    J Clin Psychiatry. 2003; 64: 459-465

  • 67.
    • Passie T
    • Emrich HM
    • Karst M
    • Brandt SD
    • Halpern JH

    Mitigation of post-traumatic stress symptoms by cannabis resin: a review of the clinical and neurobiological evidence.

    Drug Test Anal. 2012; 4: 649-659

  • 68.

    Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report.

    Perm J. 2016; 20 ()

  • 69.
    • Skrabek RQ
    • Galimova L
    • Ethans K
    • Perry D

    Nabilone for the treatment of pain in fibromyalgia.

    J Pain. 2008; 9: 164-173

  • 70.
    • Arad S
    • Bar-Lev Schleider L
    • Knanni J
    • et al.

    Medical cannabis for the treatment of Tourette syndrome: a descriptive analysis of 24 patients.

    Mov Disord. 2017; 31: S309-S310

  • 71.
    • Hasan A
    • Rothenberger A
    • Münchau A
    • Wobrock T
    • Falkai P
    • Roessner V

    Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report.

    J Clin Psychopharmacol. 2010; 30: 190-192

  • 72.

    Effective treatment of Tourette’s syndrome with marijuana.

    J Psychopharmacol. 1993; 7: 389-391

  • 73.
    • Müller-Vahl KR
    • Schneider U
    • Emrich HM

    Combined treatment of Tourette syndrome with Δ9-THC and dopamine receptor antagonists.

    J Cannabis Ther. 2002; 2: 145-154

  • 74.
    • Cooper RE
    • Williams E
    • Seegobin S
    • Tye C
    • Kuntsi J
    • Asherson P

    Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial.

    Eur Neuropsychopharmacol. 2017; 27: 795-808

  • 75.
    • Cameron C
    • Watson D
    • Robinson J

    Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation.

    J Clin Psychopharmacol. 2014; 34: 559-564

  • 76.

    The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD).

    CNS Neurosci Ther. 2009; 15: 84-88

  • 77.
    • Greer GR
    • Grob CS
    • Halberstadt AL

    PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program.

    J Psychoactive Drugs. 2014; 46: 73-77

  • 78.
    • Jetly R
    • Heber A
    • Fraser G
    • Boisvert D

    The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study.

    Psychoneuroendocrinology. 2015; 51: 585-588

  • 79.

    Medical cannabis as treatment for chronic combat PTSD: promising results in an open pilot study. Patients Out of Time Conference; Tucson, Arizona.

  • 80.
    • Quinn D
    • Hunter MA
    • Hager BW

    Medicinal cannabis reduces agitation in acquired brain injury: case study.

    J Neurotrauma. 2014; 33: A-80

  • 81.

    Post-traumatic stress disorder and medical cannabis use: a naturalistic observational study.

    Eur Neuropsychopharmacol. 2012; 22: S363-S364

  • 82.
    • Roitman P
    • Mechoulam R
    • Cooper-Kazaz R
    • Shalev A

    Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder.

    Clin Drug Investig. 2014; 34: 587-591

  • 83.
    • Wilkinson ST
    • Stefanovics E
    • Rosenheck RA

    Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder.

    J Clin Psychiatry. 2015; 76: 1174-1180

  • 84.
    • Bhattacharyya S
    • Wilson R
    • Allen P
    • Bossong M
    • Appiah-Kusi E
    • McGuire P

    Effect of cannabidiol on symptoms, distress and neurophysiological abnormalities in clinical high-risk for psychosis patients: a placebo-controlled study.

    Schizophr Bull. 2018; 44: S28

  • 85.
    • Boggs DL
    • Surti T
    • Gupta A
    • et al.

    The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.

    Psychopharmacology. 2018; 235: 1923-1932

  • 86.
    • D’Souza DC
    • Abi-Saab WM
    • Madonick S
    • et al.

    Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

    Biol Psychiatry. 2005; 57: 594-608

  • 87.
    • Goswami S
    • Mattoo SK
    • Basu D
    • Singh G

    Substance-abusing schizophrenics: do they self-medicate?.

    Am J Addict. 2004; 13: 139-150

  • 88.
    • Hallak JEC
    • Machado-de-Sousa JP
    • Crippa JAS
    • et al.

    Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD).

    Br J Psychiatry. 2010; 32: 56-61

  • 89.
    • Kolliakou A
    • Castle D
    • Sallis H
    • et al.

    Reasons for cannabis use in first-episode psychosis: does strength of endorsement change over 12 months?.

    Eur Psychiatry. 2015; 30: 152-159

  • 90.
    • Leweke FM
    • Piomelli D
    • Pahlisch F
    • et al.

    Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

    Transl Psychiatry. 2012; 2: e94

  • 91.
    • Mané A
    • Fernández-Expósito M
    • Bergé D
    • et al.

    Relationship between cannabis and psychosis: reasons for use and associated clinical variables.

    Psychiatry Res. 2015; 229: 70-74

  • 92.
    • McGuire P
    • Robson P
    • Cubala WJ
    • et al.

    Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial.

    Am J Psychiatry. 2018; 175: 225-231

  • 93.
    • Zuardi AW
    • Crippa JAS
    • Hallak JEC
    • et al.

    Cannabidiol for the treatment of psychosis in Parkinson’s disease.

    J Psychopharmacol. 2009; 23: 979-983

  • 94.
    • Zuardi AW
    • Hallak JEC
    • Dursun SM
    • et al.

    Cannabidiol monotherapy for treatment-resistant schizophrenia.

    J Psychopharmacol. 2006; 20: 683-686

  • 95.

    The health and social effects of nonmedical cannabis use.

    World Health Organization,
    Geneva2016

  • 96.
    • Mammen G
    • Rueda S
    • Roerecke M
    • Bonato S
    • Lev-Ran S
    • Rehm J

    Association of cannabis with long-term clinical symptoms in anxiety and mood disorders: a systematic review of prospective studies.

    J Clin Psychiatry. 2018; 7917r11839

  • 97.
    • Henquet C
    • Murray R
    • Linszen D
    • van Os J

    The environment and schizophrenia: the role of cannabis use.

    Schizophr Bull. 2005; 31: 608-612

  • 98.
    • Henquet C
    • Krabbendam L
    • Spauwen J
    • et al.

    Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people.

    BMJ. 2005; 330: 11

  • 99.
    • Henquet C
    • Rosa A
    • Krabbendam L
    • et al.

    An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition.

    Neuropsychopharmacology. 2006; 31: 2748-2757

  • 100.
    • Higgins JP
    • Deeks JJ
    • Altman DG

    Special topics in statistics.

    in: Cochrane handbook for systematic reviews of interventions: Cochrane book series. Cochrane,
    London2008: 481-529

  • 101.

    Cochrane handbook for systematic reviews of interventions.

    John Wiley & Sons,
    Chicester2011

  • [ad_2]

    Latest posts